Bio Techne Net Income From Continuing Ops Over Time
| TECH Stock | USD 65.25 1.16 1.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bio Techne Performance and Bio Techne Correlation. Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.143 | Dividend Share 0.32 | Earnings Share 0.49 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value—what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Bio Techne Corp and related stocks such as Moderna, Exelixis, and Biomarin Pharmaceutical Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (3.5 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| EXEL | 75.7 M | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 92.1 M | 521.3 M | 599.5 M | 629.4 M |
| BMRN | 205.8 M | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 859.1 M | (64.1 M) | 141.6 M | 147 M | 426.9 M | 490.9 M | 515.4 M |
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.5 M) | (33 M) | (83.9 M) | (202.3 M) | (242.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
| RNA | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (24.7 M) | (44.4 M) | (118 M) | (174 M) | (202.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| CAI | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (320.8 M) | (341.4 M) | (281.9 M) | (324.2 M) | (340.4 M) |
| JAZZ | 125 M | 125 M | 93.6 M | 216.3 M | 57.3 M | 329.5 M | 397.2 M | 488.8 M | 449.3 M | 523.4 M | 241.6 M | (329.7 M) | (214.1 M) | 80 M | 560.1 M | 504.1 M | 529.3 M |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| QGEN | 116.9 M | 116.9 M | 116.9 M | 116.9 M | 116.9 M | 129.9 M | 80.3 M | 40.4 M | 190.4 M | (41.5 M) | 359.2 M | 512.6 M | 423.2 M | 332.5 M | 83.6 M | 96.1 M | 91.3 M |
| CORT | (32.4 M) | (32.4 M) | (38 M) | (46 M) | (31.4 M) | (6.4 M) | 8.1 M | 129.1 M | 75.4 M | 94.2 M | 106 M | 112.5 M | 101.4 M | 106.1 M | 141.2 M | 162.4 M | 170.5 M |
Bio Techne Corp and related stocks such as Moderna, Exelixis, and Biomarin Pharmaceutical Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Bio Techne Corp | TECH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 614 McKinley Place |
| Exchange | NASDAQ Exchange |
USD 65.25
Check out Bio Techne Performance and Bio Techne Correlation. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Bio Techne technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.